-
Changing the Landscape of Screening: AI-Powered ASMS Ligand Identification
09 Sep 2025 09:07 GMT
… the race of accelerated drug discovery, the integration of … decision-maker in biotech or pharma, this session will provide … Powered ASMS Ligand Identification
In the race of accelerated drug discovery, … -maker in biotech or pharma, this session will provide …
-
Antibody drug shows promise against lung cancer in first human trial
08 Sep 2025 10:38 GMT
New Delhi, Sepember 8 (IANS): A team of researchers in China has led a first-in-human trial of an antibody drug that may provide better treatment for people with relapsed small-cell lung cancer (SCLC).
SCLC is a fast-growing, highly malignant lung cancer. …
-
Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025
08 Sep 2025 11:00 GMT
… favorable tolerability profile. By pharmacologically targeting nonrestorative sleep through antagonism … humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being … ) concomitantly with MAO inhibitors drugs. During the acute recovery …
-
Ideaya, Hengrui Pharma presented initial data from Phase 1 IDE849 trial
08 Sep 2025 01:50 GMT
IDEAYA Biosciences (IDYA) and Hengrui Pharma presented initial data from Hengrui’ … -class delta-like ligand 3-targeting Topoisomerase-1 antibody drug conjugate, in …
-
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
07 Sep 2025 16:28 GMT
… oncology company, and Hengrui Pharma, a global pharmaceutical company focused on scientific … delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) antibody drug conjugate … /.
In December 2024, Hengrui Pharma granted IDEAYA an exclusive worldwide …
-
Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer
07 Sep 2025 16:03 GMT
… . DLL3, an inhibitory Notch pathway ligand aberrantly expressed on the surface … ;kg, reinforcing the drug’s favorable therapeutic window.
Pharmacokinetic assessments revealed consistently …
-
From C481 Resistance Evasion to Platelet Preservation: Rilzabrutinib Redefines ITP Targeted Therapy
11 Sep 2025 06:04 GMT
… conformational changes in phagocytic receptor-ligand binding and activating macrophage endocytic … (PRN1008) in healthy participants. Clin Pharmacol Drug Dev. 2024;13(6):590 …
-
Regulatory Mechanism and Drug Therapy of NLRP3 Inflammasome in Recurrent Pregnancy Loss: Research Status and Prospect
06 Sep 2025 06:12 GMT
… this pathway, a single TLR ligand suffices to activate NLRP3 via … targets and inhibits the purinergic ligand-gated ion channel 7 (P2X7 … symptomatic and employs combination pharmacotherapies. The development of drugs targeting NLRP3 is …
-
Sanofi's OX40L Inhibitor Amlitelimab Shows Positive Results in Phase 3 AD Trial
10 Sep 2025 19:27 GMT
Last week, Sanofi shared positive results from the COAST 1 phase 3 study (NCT06130566) evaluating amlitelimab in adults and adolescents 12 years and older with moderate to severe atopic dermatitis (AD).1 The drug met all primary and secondary endpoints at …
-
How lung the wait for another DLL3? Data showing promise
10 Sep 2025 12:59 GMT
… Biosciences Inc. and partner Hengrui Pharmaceuticals Co. Ltd. with IDE-849 … -in-class antibody-drug conjugate targeting delta-like ligand 3 (DLL3) and … data insight Conferences Cancer Antibody-drug conjugate
About
© 1995-2025